Latest Breaking News On - Percepta nasal swab - Page 1 : comparemela.com

Veracyte, Inc (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript

Veracyte, Inc (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United statesMason carricoWilliam blairMarc stapleyJi namRebecca chambersShayla gormanAndrew brackmannBiggest real estate companiesExchange commissionMorgan stanleyVeracyte incAmerican cancer societyCall transcript mayVeracyte first quarterResults conference

Veracyte, Inc (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript

Veracyte, Inc. misses on earnings expectations. Reported EPS is $-0.39 EPS, expectations were $-0.07. Veracyte, Inc.

United statesWilliam blairMarc stapleyShayla gormanDustin scaringeJi namMason carricoRebecca chambersMorgan stanleyExchange commissionResearch useSociety of urologic oncologyNational comprehensive cancer networkVeracyte incCall transcript februaryVeracyte fourth quarter

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Grew Fourth Quarter Revenue to $98.2 million Increased 2023 Total Revenue 22% to $361.1 million Conference Call and Webcast Today at 4:30 p.m. ET .

United statesMarc stapleyCompany formNational comprehensive cancer networkVeracyte incExchange commissionGenomics incVeracyte diagnostics platformDecipher prostatePercepta nasal swabRegarding useAnnual reportQuarterly reportDecipher biosciencesMonths ended decemberStockholder equity

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Veracyte, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2023. "We closed 2023 with another quarter of excellent results, driven by our Afirma and Decipher businesses," said Marc Stapley, Veracyte's.

United statesMarc stapleyGenomics incCompany formVeracyte incExchange commissionNational comprehensive cancer networkConference callAnnounces fourth quarterVeracyte diagnostics platformDecipher prostatePercepta nasal swabRegarding useAnnual reportQuarterly reportDecipher biosciences

Global In-Vitro Diagnostics Market to Record Robust Growth, Accounting for $176 23 Billion by 2030, as Prevalence of Chronic Illnesses Rises, Projects Kings Research

/PRNewswire/ According to the latest report by Kings Research, the global In-Vitro Diagnostics Market was worth USD 145.29 billion in 2022 and is projected.

United statesUnited arab emiratesSiemens healthineersCompany market rankingResearch methodologyBurjeel holdingsPorter five forces analysisIllumina form partnership for advancedKings researchCompany profilesPremium researchSysmex corporationVitro diagnostics market developmentResearch flowDanaher corporationAbbott laboratories